血友病B的因子IX-Padua AAV基因治疗:1/2期和3期试验
在中国开展的单臂剂量递增1/2期试验(6例男性)和多中心3期试验(26例血友病B患者)评估AAV-因子IX Padua基因治疗(BBM-H901)。1/2期试验5×10^12 vg/kg剂量下10周内未观察到剂量限制性毒性;3期试验输注后52周内平均年化出血率降至0.60(95%CI 0.18-1.99),95%CI上限1.99低于预设优效界值5.0,80.8%参与者零出血。
要点
- 1/2期试验5×10^12 vg/kg剂量下10周内未观察到剂量限制性毒性。
- 3期试验输注后52周内平均年化出血率为0.60(95%CI 0.18-1.99)。
- 3期试验第52周载体衍生FIX:C均值为41.9(28.7)IU/dl,80.8%参与者零出血。
核心结论
- 本研究支持AAV-FIX Padua基因治疗在中国大型队列中的安全性和有效性。
研究设计与样本
- 单臂剂量递增1/2期试验纳入6例男性血友病B参与者,测试5×10^12 vg/kg剂量,主要终点为剂量限制性毒性和不良事件。
- 多中心3期试验纳入26例中国血友病B患者,测试1/2期确定的5×10^12 vg/kg剂量,主要终点为基因治疗后年化出血率。
主要发现
- 1/2期试验10周内未观察到剂量限制性毒性,最常见药物相关不良事件为转氨酶升高(33.3%),52周内未发生3级药物相关不良事件。
- 3期试验输注后52周内平均年化出血率降至0.60(95%CI 0.18-1.99),95%CI上限1.99低于预设优效界值5.0。
- 3期试验最常见药物相关不良事件同样为转氨酶升高,第52周载体衍生FIX:C均值为41.9(28.7)IU/dl。
- 3期试验中无参与者存在目标关节,80.8%参与者在52周随访期间零出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene therapy for hemophilia B with adeno-associated virus (AAV) vector has achieved great advances over the last decade. We previously conducted a pilot study demonstrating the safety and efficacy of AAV-factor IX (FIX) Padua gene therapy (BBM-H901) in ten male participants with hemophilia B. Here we report a single-arm dose-escalation phase 1/2 trial in 6 male participants and a multicentre phase 3 trial in 26 participants with hemophilia B in China. The phase 1/2 study tested a dose of 5 × 1012 vg kg-1 (n = 6), with primary endpoints assessing dose-limiting toxicities (DLT) and adverse events (AEs). The primary endpoint was met with no DLT observed in the 10 weeks postinfusion. The most common drug-related AEs were transaminitis (33.3%), and no grade 3 drug-related AE occurred within 52 weeks postintervention. The phase 3 study tested the 5 × 1012 vg kg-1 dose, as determined in the phase 1/2 study, in 26 patients. The primary endpoint evaluated the annualized bleeding rate (ABR) after gene therapy and secondary endpoints included vector-derived FIX:C, target joint and percentage of participants with zero bleeds postgene therapy. The study met its primary endpoint as the mean (95% confidence interval (CI)) ABR within 52 weeks after BBM-H901 infusion decreased to 0.60 (0.18-1.99), and the upper limit of the 95% CI (1.99) was lower than the predefined superiority margin of 5.0 (historical ABR assumed for patients receiving prophylactic FIX treatment in China). In the phase 3 trial, the most common drug-related AEs were transaminitis as well, and the vector-derived FIX:C had a mean of 41.9 (28.7) IU dl-1 at week 52. None of the participants had a target joint, and 80.8% of participants experienced zero bleeds during the 52-week follow-up. Our study supports the safety and efficacy of AAV-FIX Padua gene therapy in a large Chinese cohort. ClinicalTrials.gov registration: NCT05203679 .
引用
- Xue F, Ju M, Zhu T, et al. Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. Nat Med. 2025. PMID: 41266685. doi:10.1038/s41591-025-04012-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。